RxDoctor Payments Data

Jaymi Smith, APRN

Family · Lawton, OKNPI 1992108773

Payments from drug & device makers

$519in general payments, 2019–2025

Across 29 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$116
  • Pfizer$90
  • Esperion Therapeutics, Inc.$49
  • Exact Sciences$46
  • AstraZeneca$30
  • Halozyme Inc$27
  • plus $161 from 10 others

What the payments were for

  • Food & beverage$519100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$519 in reported general payments places this provider in the 55th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$91
Medicare patients
16
Services billed
16

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$49,667
JanuviaSitagliptin Phosphate59$47,973
EliquisApixaban29$32,358
TrulicityDulaglutide21$22,938
JardianceEmpagliflozin15$17,855
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,523
XareltoRivaroxaban12$7,996
Tresiba Flextouch U-100Insulin Degludec13$7,919
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,551
SymbicortBudesonide/Formoterol Fumarate11$4,346
Atorvastatin Calcium214$2,448
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,219
Levothyroxine Sodium188$2,166
Losartan Potassium104$1,310
Lidocaine17$1,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$49,66750 claims
PfizerEliquis$90$32,35829 claims
Lilly USA, LLCTrulicity$116$22,93821 claims
GSKTrelegy Ellipta$15$10,52315 claims
AstraZenecaSymbicort$30$4,34611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,026 family providers in Oklahoma.

Other family in Lawton

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →